| Fully Human |
MIMIC™ technology is based on autologous primary human immune cells. One surrogate human provides all controls (no drug, drug, drug + pathogen) and can be repeated multiple times. |
| Cost Effective |
Because the MIMIC™ System is predictive, it can lead to faster cycle times for discovery and reduce the time and costs to bring drugs to the market. |
| Diverse |
The MIMIC™ process can include a diverse donor pool comprising hundreds of individuals. |
| Comprehensive |
The MIMIC™ System models innate and/or adaptive and functional immune responses; analysis is available for cytokines, APCs, T cells, and B cells for a better selection of drug candidates for clinical evaluation. |
| Modular |
MIMIC™ processing is high-throughput and automated with approximately 10,000 assays per month. |
| Sensitive |
MIMIC™ technology is more sensitive than standard PBMC assays. Read our case studies for details. |
MIMIC™ System Compared to Traditional Methods
There are two general approaches used to predict human immune responses: animal models and human in vitro models.
| |
Animal |
PBMC |
MIMIC |
| Physiological environment |
Y |
N |
Y |
| Uses human cells |
N |
Y |
Y |
| High sensitivity |
Y |
N |
Y |
| High-throughput format |
N |
Y |
Y |
| Cost-effective |
N |
Y |
Y |
| Captures human diversity |
N |
N |
Y |